Other languages Virios Therapeutics, Inc.

Equities

VIRI

US92829J1043

Delayed Nasdaq Other stock markets 02:47:18 2024-04-29 pm EDT			5-day change	1st Jan Change
0.4624 ^USD	-1.51%		+8.62%	-19.58%

Feb. 29	Virios Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
Jan. 22	Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Virios Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29
Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid	Jan. 22
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID	Jan. 02
Virios Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Virios Therapeutics, Inc. Announces Termination of At-The-Market Sales Agreement	23-09-18
Virios Therapeutics Shares Slump After Company Reports Q2 Loss	23-08-10
Virios Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Virios Therapeutics, Inc. Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as A New Treatment Option for Fibromyalgia	23-08-09
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-Covid Symptoms Following Treatment with A Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study	23-07-17
Virios Therapeutics Regains Compliance With Nasdaq Listing Rule	23-05-26
Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Virios Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14
Virios Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14
Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023	23-02-13
Better-Than-Expected Inflation Data Seen Boosting US Equities	22-12-13
US Stock Futures Move Higher Ahead of November Inflation Data	22-12-13
Virios Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14
Sector Update: Health Care Stocks Struggle on Tuesday	22-09-20
Sector Update: Health Care Stocks Dropping in Afternoon Trade	22-09-20
Sector Update: Health Care	22-09-20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Virios Therapeutics, Inc.

Equities

VIRI

US92829J1043

Other languages

Filters